Innovent Biologics and Roche have entered into an exclusive global license agreement to advance IBI3009, a novel DLL3-targeted antibody-drug conjugate (ADC) for the treatment of small cell lung cancer. #InnoventBiologics #Roche #globallicenseagreement #antibodydrugconjugate #ADC #smallcelllungcancer #pharmanews #pharmamanufacturing https://lnkd.in/gMFW6P8B
Pharma Manufacturing’s Post
More Relevant Posts
-
Screenwriter - Blending reality and fiction: where science meets captivating storytelling.
#China’s #CanSino Biologics' PD-1/VEGF New Drug Eboxizumab Sparks Revolution in Lung Cancer. It is currently approved in China for use in combination with pemetrexed and carboplatin for the treatment of EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC patients. https://lnkd.in/g_JHQ8un
-
-
Under-the-skin Keytruda comparable to infused version in Phase 3 study, Merck says https://lnkd.in/gBu9dTGt An experimental under-the-skin injection of Merck & Co.’s cancer immunotherapy Keytruda showed similar characteristics as the current intravenous formulation in a Phase 3 clinical trial, the company said Tuesday. The drugmaker plans to discuss data [...]
-
Wow, looks like some very compelling data from #SummitTherapeutics for #Ivonescimab (a bi-specific antibody drug) in both #PDL1 "moderate" as well as "high" tumors in #NSCLC... will be interesting to follow the next steps, since the study was conducted solely in #china.
Summit's Phase 3 data back up biotech's boasts of beating Keytruda in lung cancer
endpts.com
-
Successful preclinical testing of your investigational cancer therapy depends on choosing the right model. Learn more by downloading our white paper! https://hubs.ly/Q02rJrvQ0 #Inotiv #Oncology #R2G2mouse
How can Inotiv's R2G2® mouse advance your oncology study?
insights.inotivco.com
-
Check out DIMA's Solution to Drive ADC Excellence ADCs (Antibody-Drug Conjugates) combine the targeted precision of monoclonal antibodies with the potent impact of small-molecule cytotoxic drugs. This transformative approach not only advances the accuracy of cancer treatment but also minimize the undesired side effects associated with traditional therapies. The key to successful ADC development lies in the selection of the right antibody molecules, a pivotal factor in ensuring the efficacy and safety of these groundbreaking therapies. Visit the following page to learn: 1. DIMA’s ADC development process 2. Case Studies 3. Unique Tools for ADC Advancement https://lnkd.in/ewb5GvtE
-
-
Zai Lab's partners Pfizer and Genmab jointly announced that the US FDA has approved their supplementary Biologics License Application (sBLA) for TIVDAK(®). This sets the stage for its use in the treatment of patients who are suffering from recurrent or metastatic cervical cancer, whose condition has progressed during or after chemotherapy. There's a considerable unmet need for cervical cancer treatment. The disease - recurrent and/or metastatic cervical cancer - is extremely destructive and often incurable; statistics show that up to 15% of adult cervical cancer patients experience metastasis at diagnosis, and for those diagnosed early and treated, as many as 61%(v) suffer recurrences. #QMportfolio #QMhealthcare #ZaiLab #Pfizer #Genmab #FDA #TIVDAKApproval #CervicalCancerTreatment
-
-
𝗖𝗿𝗶𝘁𝗶𝗰𝗮𝗹 𝗺𝗲𝗱𝗶𝗮𝘁𝗼𝗿 𝗼𝗳 𝗹𝘂𝗻𝗴 𝗰𝗮𝗻𝗰𝗲𝗿 𝗿𝗲𝘀𝗶𝘀𝘁𝗮𝗻𝗰𝗲 𝗶𝗱𝗲𝗻𝘁𝗶𝗳𝗶𝗲𝗱! A recent study that used our TRC research chemicals (TRC-M325750) identified a critical mediator of lung cancer drug resistance. Read the findings in the journal Oncogene: https://okt.to/Xl2MkY 🌟Our extensive cancer portfolio can help from target identification to drug development and generics manufacturing. Explore now: https://okt.to/oAOlv9 #LungCancer #ProductCitation #oncologyresearch #ResearchChemicals
TWIST1 is a critical downstream target of the HGF/MET pathway and is required for MET driven acquired resistance in oncogene driven lung cancer - Oncogene
-
Biotech M.S. grad | Eurofins Advinus | Discovery Services | Innovation and strategic collaboration | Let's connect! #Happy_Analysing 🌐
🔬 As biotechnologists, we often rely on antibodies to characterize various biological properties and phenotypes in our daily work. However, delving into the characterization of therapeutic antibodies can provide valuable insights that enhance our understanding and drive innovation. Let's continue to explore the potential of these powerful concept! #Biotech #AntibodyResearch #Innovation #DrugDiscovery #Therapeutics
How do you comprehensively characterize therapeutic antibodies? Don’t miss out on this case study demonstrating our molecular approach to thoroughly characterize trastuzumab, a humanized monoclonal antibody targeted against the ErbB2 protein and approved to treat HER2-positive breast cancer. This case study highlights guidelines from regulatory agencies regarding monoclonal antibodies. It shows how the Eurofins Discovery approach provides you with the robust, reliable, and quality data you need to make confident decisions that will progress your program into preclinical development. Download now to see how Eurofins Discovery’s safety screening and profiling vigilance can save you time and resources in your biotherapeutics program. Get more details: https://lnkd.in/gnNk_7VQ #biotherapeutics #trastuzumab #drugdiscovery #eurofinsdiscovery
-
Helping pharmaceutical companies grow their business, protect their assets, find better partners and minimize their pain points
The newest report from Clarivate is out. Download it now!
Antibody drug conjugates (ADCs) are emerging as a powerful platform for delivering highly targeted doses of oncology and potentially other drugs to patients with a minimum of side effects and toxicity. Large pharmas are anxious to partner with or acquire ADC makers to access this technology. The new 2024 Companies to Watch report highlights seven innovative companies advancing antibody-drug conjugates (ADCs) to deliver highly targeted cancer treatments with minimal side effects. Download the report: https://lnkd.in/eCSaAWtu #oncology #cancertreatment #drugdiscovery #pharma
-
-
I am happy to share my first Review article as the first author entitled "Deciphering the US Regulatory Framework: Comparison Between Oncology Biosimilars and Reference Biologics" 📄 This study highlights how biosimilars provide affordable, safe alternatives to biologics in oncology, helping improve access to cancer care. 💊💡 I am thankful to my co-authors Priya Varpe and Purva Chaugule for their incredible collaboration and to Dr. Saurabh Srivastava, Ph.D. for his constant guidance and support. #Biosimilars #Oncology #RegulatoryAffairs #Publication Link to access the article: http://bit.ly/4fw7lSD
-
